It’s time for Irish genomes to come home.
| Genomics | Health disparities |
| Epigenetics | Medical genetics |
| Genomics | Health disparities |
| Epigenetics | Medical genetics |
It’s time for Irish genomes to come home.
I'm going to lift over this LinkedIn post
https://www.linkedin.com/feed/update/urn:li:activity:7085340387233406976/
Probably not very many people here interested in the dynamics of the DNA sequencing market. But I’m going to post it anyway!
https://aseq.substack.com/p/illuminas-sorrow-and-desouzas-woes?sd=pf
There’s an interesting article on Illumina in the FT. It’s well worth reading but I’ve listed what I think are the key quotes below: Within the next few weeks Brussels is expected to hit it [Illumina] with a fine of up to 10 per cent of revenues or about $450mn, for closing the Grail deal despite opposition from regulators.
Quoting @[email protected] among others, the value of bringing all groups into genomics research is proposed.
Combined Winter party for @[email protected] labs of myself, @[email protected] and @[email protected]
Great to be able to catch up and see old friends who popped by to say hello.
There’s a 2021 paper from a Norwegian group that precedes this new preprint:
Intraoperative nanopore sequencing combined with machine learning diagnostics was robust, sensitive, and rapid. This strategy allowed DNA methylation-based classification of the tumor to be returned to the surgeon within a timeframe that supports intraoperative decision making.